Introduction
============

Most neurodegenerative diseases are characterized by the accumulation of misfolded proteins. Thus, α-synuclein aggregates in Parkinson's disease and other synucleinopathies, TDP-43 (TAR DNA-binding protein 43) in TDP-43 proteinopathies, huntingtin in Huntington's disease and both β-amyloid and tau in Alzheimer's disease ([@aws143-B12]). Filaments made of hyperphosphorylated tau protein are a good predictor of the cognitive state in Alzheimer's disease, because a negative correlation has been described between the number of neurofibrillary tangles, and the Mini-Mental score ([@aws143-B11]). Tau deposits also constitute the defining pathological hallmark of several other diseases, including progressive supranuclear palsy, corticobasal degeneration, Pick's disease and frontotemporal dementia and parkinsonism linked to chromosome 17 ([@aws143-B13]; [@aws143-B15]). Since filament assembly is a concentration-dependent process, a reduction in the production and/or increased clearance of tau are potential targets.

In eukaryotic cells, there are two major systems responsible for the degradation of cytoplasmic proteins: the ubiquitin--proteasome system and the autophagy--lysosome pathway ([@aws143-B16]). The accumulation of ubiquitinated tau in intracellular filamentous inclusions suggests a possible impairment of tau degradation by the ubiquitin--proteasome system and/or the autophagy--lysosome pathway. Indeed, inactivation of the ubiquitin--proteasome system or the autophagy--lysosome pathway has been reported to lead to neurodegeneration associated with the presence of ubiquitinated aggregates ([@aws143-B18]; [@aws143-B21]; [@aws143-B2]; [@aws143-B44]). Particularly, ubiquitin--proteasome system or autophagy--lysosome pathway inhibition induces the accumulation of tau ([@aws143-B5]; [@aws143-B42]; [@aws143-B29]; [@aws143-B25]). Moreover, accumulation of autophagic vacuoles has been observed in Alzheimer's disease brain and in a mouse model of tauopathy ([@aws143-B27]; [@aws143-B33]), suggesting a possible disturbance of lysosomal proteolysis in tauopathy. Macroautophagy (hereafter referred to as autophagy) is the major form of autophagy. Although it is known that the suppression of autophagy causes neurodegeneration ([@aws143-B18]), relatively little is known about the role of autophagy in animal models of human tauopathy. In the triple transgenic mouse model of Alzheimer's disease and in a mouse model expressing human mutant tau on a null background for the E3 ubiquitin ligase parkin, stimulation of autophagy promoted the degradation of insoluble tau ([@aws143-B6]; [@aws143-B30]; [@aws143-B45]). However, these studies did not allow one to determine whether the effects of autophagy stimulation were due to a direct interaction between the autophagic machinery and tau or whether they were indirect. To date, there has been no report of the effect of increased autophagy in a mouse model of human tauopathy. We therefore administered trehalose, a mammalian target of rapamycin (mTOR)-independent activator of autophagy ([@aws143-B34]; [@aws143-B46]), to mice transgenic for human mutant P301S tau.

Materials and methods
=====================

Antibodies
----------

We used phosphorylation-independent anti-tau antibodies BR133 and BR134 which recognize both murine and human tau isoforms. Phosphorylation-dependent anti-tau antibodies AT8 and AT100 (Innogenetics) were also used. AT8 recognizes tau protein phosphorylated at S202 and T205 ([@aws143-B14]), whereas AT100 detects tau phosphorylated at T212, S214 and T217 ([@aws143-B55]). Autophagy was assessed using an antibody against microtubule-associated protein light chain 3 (LC3) (Novus Biologicals). We also used an antibody against p62/SQSTM1 (Santa Cruz Biotechnology). To normalize protein levels, an anti-GAPDH (Millipore, Ltd.) antibody was used.

Animals and treatment
---------------------

Homozygous human P301S tau transgenic mice ([@aws143-B1]) and age-matched wild-type C57BL/6 mice were used (*n* = 6 per group for western blot analysis; *n* = 3 per group for immunohistochemistry and stereology experiments). From weaning onwards, the animals were treated with 2% trehalose or 2% sucrose, which were used as the control. A separate group received normal drinking water (no treatment). The water solutions were changed twice weekly. Animals were checked daily and the quantity of water drunk and the animals' weights were assessed twice a week. P301S tau transgenic mice develop motor deficits at ∼3--4 months of age, as shown using Rotarod ([@aws143-B48]). We routinely evaluated these deficits by visual inspection, as they form in a stereotypical manner consisting of an unstable gait followed by general stiffness and hindlimb paralysis. Furthermore, at 3--4 months of age, the human P301S tau mice are unable to extend their hindlimbs when lifted by the tail ([@aws143-B1]). In this study, we assessed the motor deficits by visual inspection and used the time when all the animals had developed hindleg stiffness and were unable to extend their hindlimbs when suspended by the tail as the endpoint (20 weeks of age).

Tissue extraction
-----------------

To extract sarkosyl-insoluble proteins from brain and spinal cord, frozen tissues were weighed and homogenized in cold extraction buffer \[10 mM Tris--HCl, pH 7.4, 800 mM NaCl, 1 mM EGTA, 0.1 M phenylmethylsulphonyl fluoride, 10% sucrose and one tablet of complete protease inhibitor cocktail (Roche)\]. The homogenates were spun at 6000*g* for 20 min and the supernatants incubated with 1% sarkosyl for 1 h at room temperature. After a 1 h centrifugation at 80 000 *g*, the supernatants were discarded and the pellets resuspended in 50 mM Tris--HCl, pH 7.4 (300 µl/g tissue). For investigation of soluble tau, brains and spinal cords were homogenized in 25 mM Tris--HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulphonyl fluoride and one tablet of complete protease inhibitor cocktail. Samples were centrifuged at 80 000 *g* for 15 min. The resulting supernatant constituted the soluble fraction. The samples were analysed by SDS-PAGE.

Immunoblot analysis
-------------------

After SDS-PAGE, the gels were blotted for 1 h at room temperature onto polyvinylidene difluoride membranes (Millipore). The membranes were blocked for 1 h at room temperature in 0.1 M phosphate buffer, pH 7.4, 0.2% Tween 20 and 5% milk, followed by an overnight incubation with the primary antibody in blocking buffer. Membranes were then washed in 0.1 M phosphate buffer, pH 7.4, 0.2% Tween 20 and incubated for 1 h at room temperature with peroxidase-conjugated secondary antibody (Pierce) in blocking solution. After washing, the blots were developed using enhanced chemiluminescence (Amersham Biosciences).

Quantification of proteins
--------------------------

Band intensities were quantified (Chemidoc™ XRS and Quantity One® software, Bio-Rad) and the amounts of soluble proteins normalized with respect to GAPDH. Insoluble tau was normalized relative to the tissue weight. Data were expressed as means ± SEM. Statistical analysis was performed using a one-way ANOVA test followed by Tukey's *post hoc* comparisons (Prism, GraphPad Software, Inc.).

Immunohistochemistry
--------------------

Mice were perfused transcardially with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Brains and spinal cords were dissected and post-fixed overnight at 4°C, followed by cryoprotection in PBS containing 30% sucrose for at least 24 h. Serial sagittal brain sections (30 µm) were cut on a Leica SM2400 microtome (Leica Microsystems) and stored at 4°C in PBS containing 0.1% sodium azide. For fluorescence labelling, sections were permeabilized for 5 min with cold PBS containing 0.5% Triton X-100 and washed three times with PBS, 0.1% Triton X-100 (PBST). After 2 h blocking at room temperature with PBST containing 3% bovine serum albumin, sections were incubated with the primary antibodies in blocking solution for 24 h at 4°C. This was followed by three washes and a 2 h incubation at room temperature with Alexa Fluor® 488 (Molecular Probes) or Cy5 (Abcam) secondary antibodies in blocking solution. After washing and DAPI (4,6-diamidino-2-phenylindole) staining, the sections were mounted using Vectashield mounting medium (Vector Laboratories). They were analysed using a Leica DMRB fluorescence microscope (Leica) or a Radiance 2100 confocal microscope (Bio-Rad). Images were taken using a Sharp 2000 laser (Zeiss Bio-Rad) and were typically 512 × 512 pixels. Staining for neuronal nuclei (NeuN; Chemicon) ([@aws143-B32]; [@aws143-B54]; [@aws143-B28]) and tau phosphorylated at the AT100 epitope were carried out in brains of wild-type and transgenic mice using immunoperoxidase (Vectastain ABC kit, Vector Laboratories). Endogenous peroxidase was quenched for 15 min with 3% H~2~O~2~ in distilled water. After washing, sections were blocked for 1 h with normal horse serum in PBST and incubated overnight with the anti-NeuN antibody (1:500) in blocking solution at 4°C. After three rinses with PBST, sections were incubated with a biotin-conjugated anti-mouse antibody for 2 h at room temperature. Next, the avidin--biotin-conjugated complex was applied for a further 2 h. Finally, the antigen was visualized using the Vector® VIP substrate kit (Vector Laboratories). Sections were mounted on SuperFrost® glass slides (VWR international) and dehydrated using a series of ascending ethanol solutions (70, 95 and 100%) and xylene.

Stereology
----------

The Stereo Investigator 9 (MBF Bioscience) was used to quantify the number of NeuN-positive cells. Sections through the brain were sampled in a systematic random manner using 1:12 series for quantification of NeuN-positive and AT100-positive neurons. The thickness of each section was determined using the Stereo Investigator 9 software. For a given section, the outline of the region of interest was traced under a ×10 objective and the enclosed area calculated by the software. Sections within the highlighted area were then sampled at random and cells counted under the ×40 objective to determine the total number of immunoreactive cells. Statistical analyses were performed using a one-way ANOVA test followed by Tukey's *post hoc* comparisons (Prism, GraphPad Software, Inc.).

Results
=======

Animal health
-------------

Water consumption of the three groups (no treatment, sucrose-treated and trehalose-treated) was similar. Sucrose and trehalose had no impact on the animals' weights or coat aspects, suggesting that the health of the mice was similar among the three groups. The human P301S tau mice were sacrificed at 20 weeks of age, when they developed an unstable gait and motor abnormalities, which is typical of homozygous transgenic mice ([@aws143-B1]). The development of motor deficits was not significantly different between treated and non-treated human P301S tau transgenic mice. Thus, untreated mice developed the first motor deficits at 19 ± 0.19 weeks of age, which was not significantly different from the ages at which they appeared in sucrose-treated (18.8 ± 0.31 weeks) and trehalose-treated (19.25 ± 0.23 weeks) mice ([Supplementary Fig. 1](http://brain.oxfordjournals.org/cgi/content/full/aws143/DC1)).

Effects of trehalose on autophagy activation
--------------------------------------------

To investigate autophagy activation, we measured the conversion of LC3-I into LC3-II, a marker of autophagic vacuole formation ([@aws143-B20]; [@aws143-B31]; [@aws143-B51]). We observed the conversion of 17.5 ± 2.3% LC3-I into LC3-II in the brains of trehalose-treated mice, while no detectable LC3-I conversion was seen in untreated or sucrose-treated mice ([Fig. 1](#aws143-F1){ref-type="fig"}A). Unexpectedly, trehalose had no effect on LC3-I conversion in the spinal cord ([Fig. 1](#aws143-F1){ref-type="fig"}B). We therefore focused our study on the brain. Immunohistochemistry of brain sections from mice transgenic for human mutant P301S tau showed the presence of LC3 puncta in trehalose-treated mice ([Fig. 1](#aws143-F1){ref-type="fig"}E). The punctate distribution of LC3 was absent from control groups ([Fig. 1](#aws143-F1){ref-type="fig"}C and D). In trehalose-treated transgenic mice, AT100-positive tau aggregates were also immunoreactive for LC3, indicating the co-localization of autophagic vacuoles and tau aggregates (arrows, [Fig. 1](#aws143-F1){ref-type="fig"}F--H). Figure 1Conversion of LC3-I into LC3-II was assessed by western blotting in the spinal cord (**A**) and the brain (**B**) of mice transgenic for human P301S tau. LC3-II staining was only present in brain where autophagic vacuoles were observed in trehalose-treated mice (arrow in **E**). Autophagic vacuoles were not present in the brains of non-treated (**C**) or sucrose-treated (**D**) mice. (**F--H**) Confocal analysis indicated that AT100-positive tau inclusions (**F**) were also immunoreactive for LC3-II (**G**), suggesting the presence of tau inclusions in autophagic vacuoles in trehalose-treated transgenic mice (**H**). NT = no treatment; Su = sucrose-treated; Tr = trehalose-treated. Scale bar = 20 µm.

Effects of trehalose on tau pathology and neuronal survival
-----------------------------------------------------------

Total soluble tau and soluble tau phosphorylated at the AT8 epitope were not affected by trehalose treatment ([Supplementary Fig. 2](http://brain.oxfordjournals.org/cgi/content/full/aws143/DC1)). In contrast, quantification of sarkosyl-insoluble tau in the brain indicated that trehalose decreased the amount of insoluble tau compared with untreated controls (−53%, *P* \< 0.01) or to controls treated with sucrose (−46%, *P* \< 0.05) ([Fig. 2](#aws143-F2){ref-type="fig"}A). Trehalose treatment had no effect on the amount of sarkosyl-insoluble tau in the spinal cord ([Fig. 2](#aws143-F2){ref-type="fig"}B). Immunofluorescence staining for anti-tau antibody AT100 showed a drastic reduction in the number of positive cells in layers I--III of the cerebral cortex (−66.5% compared with untreated animals, *P* \< 0.01; −80.1% compared with sucrose-treated mice, *P* \< 0.001) ([Fig. 2](#aws143-F2){ref-type="fig"}C--F) and in the brainstem, particularly the pontine nucleus (−75% compared with untreated animals, *P* \< 0.001; −58.6% compared with sucrose-treated mice, *P* \< 0.01) ([Fig. 2](#aws143-F2){ref-type="fig"}G--J). Nerve cell numbers were counted in layers I--III of the cerebral cortex and in the pontine nucleus. The number of neurons in layers I--III was higher in trehalose-treated P301S tau mice than in animals that received either no treatment (+55.5%, *P* \< 0.05) or were treated with sucrose (+59.6%, *P* \< 0.05) ([Fig. 3](#aws143-F3){ref-type="fig"}A). The number of neurons in trehalose-treated mice and in untreated wild-type animals was not significantly different ([Fig. 3](#aws143-F3){ref-type="fig"}A). In the pontine nucleus, the number of neurons increased in trehalose-treated animals compared with untreated (+79.2%, *P* \< 0.01) and sucrose-treated controls (+61.6%, *P* \< 0.05) ([Fig. 3](#aws143-F3){ref-type="fig"}B). The number of NeuN-positive cells in the pontine nucleus was similar in trehalose-treated P301S tau mice and in wild-type controls ([Fig. 3](#aws143-F3){ref-type="fig"}B). Figure 2Sarkosyl-insoluble tau was decreased in the brain of trehalose-treated mice compared with non-treated or sucrose-treated animals (**A**), while trehalose treatment had no effect on sarkosyl-insoluble tau in the spinal cord (**B**). In trehalose-treated mice, the number of nerve cells with AT100-positive inclusions was drastically reduced in layers I--III of the cerebral cortex (**C--F**) and in the pontine nucleus of the brainstem (**G--J**). NT = no treatment; Su = sucrose-treated; Tr = trehalose-treated. \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001. Figure 3Nerve cell numbers were assessed using stereology. Trehalose treatment increased the number of neurons in layers I--III of the cerebral cortex (**A**) and in the pontine nucleus of the brainstem (**B**). \**P* \< 0.05 and \*\**P* \< 0.01.

Effects of trehalose on p62/SQSTM1
----------------------------------

Immunohistochemistry revealed the co-localization of p62/SQSTM1 and AT100-positive tau aggregates in P301S tau transgenic mice ([Fig. 4](#aws143-F4){ref-type="fig"}D--F), while no co-staining was observed in wild-type controls ([Fig. 4](#aws143-F4){ref-type="fig"}A--C). We assessed the levels of p62/SQSTM1 in the brains of wild-type and transgenic P301S tau mice subjected to the different treatments. We observed a reduction in p62/SQSTM1 levels in mice treated with trehalose compared with mice that received either no treatment (−52.1%, *P* \< 0.05) or sucrose (−46.7%, *P* \< 0.05) ([Fig. 4](#aws143-F4){ref-type="fig"}G). No significant difference was detected between wild-type controls and P301S tau transgenic mice ([Fig. 4](#aws143-F4){ref-type="fig"}G). Figure 4Immunohistochemistry for p62/SQSTM1 (**A** and **D**) and assembled tau (AT100; **B** and **E**) showed co-localization in P301S tau transgenic mice (**F**) but not in wild-type animals (**C**). Scale bar = 20 µm. (**G**) Western blot of p62/SQSTM1 levels in the brains of wild-type controls and mice transgenic for human mutant P301S tau that received either no treatment or were given sucrose or trehalose. The amount of p62/SQSTM1 signal is shown normalized with respect to GAPDH. \**P* \< 0.05 and \*\**P* \< 0.01.

Discussion
==========

The assembly of normally soluble proteins into amyloid-like fibrils is a pathological hallmark of several neurodegenerative disorders, with tauopathies being the most common ([@aws143-B12]). Herein, we report on the effects of stimulation of autophagy on tau inclusions and nerve cell survival in a mouse line transgenic for human mutant P301S tau. Trehalose activated autophagy in the brain, as shown by the increased formation of LC3-II, and reduced the level of sarkosyl-insoluble tau. However, it did not stimulate autophagy in the spinal cord and consequently had no effect on the level of insoluble tau. The mechanism of action of trehalose is not completely understood, but it is believed to activate autophagy in an mTOR-independent manner ([@aws143-B46]). These findings suggest that autophagic pathways may differ between brain and spinal cord. The absence of a detectable effect of trehalose in the spinal cord probably accounted for the persistence of a pathological motor phenotype in treated P301S tau transgenic mice. We cannot exclude that a detailed behavioural assessment could have revealed subtle differences between treated and non-treated mice. However, the motor deficit characteristic of the human P301S tau transgenic mice probably results from the degeneration of spinal cord motor neurons, consequent to the development of a toxic filamentous tau pathology ([@aws143-B1]; [@aws143-B10]), and possibly the sequestration of proteins important for motor behaviour. As tau pathology in the spinal cord was unchanged after trehalose administration, an improvement in motor function was unlikely. The reasons underlying our inability to activate autophagy in the spinal cord remain to be determined. They could be related to a less efficient delivery of trehalose to the spinal cord, although it has been shown that the blood--spinal cord barrier is more permeable to tracers and cytokines than the blood--brain barrier ([@aws143-B41]; [@aws143-B38]). We hope that future experiments will allow us to overcome this limitation.

In the brains of trehalose-treated mice, we observed a decrease in sarkosyl-insoluble tau and the number of nerve cells with tau inclusions. Besides its ability to activate autophagy, trehalose has also been reported to act as a protective chaperone in a murine model of Huntington's disease ([@aws143-B50]). However, the reduction in tau inclusions in our mouse line was probably due to the degradation of tau aggregates by trehalose-induced autophagy. Indeed, we observed a decrease in tau inclusions only in regions where autophagy was activated. Moreover, we showed co-localization between autophagic vacuoles and tau inclusions, suggesting that tau aggregates were engulfed by autophagosomes before degradation. Sucrose, a chemical chaperone, which has been shown to reduce the conversion of the cellular prion protein to its protease-resistant form ([@aws143-B9]), failed to reduce tau aggregates in the human mutant P301S tau transgenic mice, confirming that the effect of trehalose on tau aggregates was mediated through an increase in autophagy.

Altogether, our results indicate that the *in vivo* stimulation of autophagy reduced the amount of tau aggregates and improved nerve cell survival. A role for autophagy in the clearance of protein aggregates has been suggested for a number of proteins, including β-amyloid, α-synuclein, ataxin-3, prion protein and huntingtin ([@aws143-B53]; [@aws143-B47]; [@aws143-B40]; [@aws143-B19]; [@aws143-B7]; [@aws143-B30]; [@aws143-B43]; [@aws143-B49]). Activation of autophagy has also shown protective effects in mouse and fly models of tauopathy ([@aws143-B3]; [@aws143-B6]; [@aws143-B30]; [@aws143-B45]). However, in mice, tau was not the only engineered protein. In one study, the mice overexpressed human mutant tau and carried a deletion of the gene encoding parkin ([@aws143-B45]), a potential mediator of autophagy ([@aws143-B37]; [@aws143-B8]). Therefore, not surprisingly, restoration of autophagic activity decreased the number of tau aggregates and improved cell survival. In separate studies, autophagy was activated in triple transgenic mice exhibiting tau and β-amyloid pathologies ([@aws143-B6]; [@aws143-B30]). It is well established that β-amyloid can promote tau pathology in some brain regions ([@aws143-B17]; [@aws143-B26]; [@aws143-B36], [@aws143-B35]). However, direct evidence for the relevance of autophagy in modulating tau pathology was missing. We now show that the activation of autophagy markedly reduced the number of tau aggregates and nerve cell loss in a mouse model of human tauopathy.

We also investigated p62/SQSTM1 expression in wild-type and P301S tau transgenic mice. p62/SQSTM1 is a protein that acts as a receptor for selective autophagy, mainly because of its ability to bind both ubiquitin and LC3 ([@aws143-B39]; [@aws143-B24]). It has previously been implicated in the degradation of protein inclusions ([@aws143-B4]; [@aws143-B52]) and has been found in tau inclusions in human neurodegenerative diseases ([@aws143-B22], [@aws143-B23]; [@aws143-B56]). We now show co-localization of p62/SQSTM1 with tau inclusions in P301S tau transgenic mice, consistent with the human pathology. In addition, we observed a decrease in p62/SQSTM1 levels in trehalose-treated mice, suggesting that p62/SQSTM1 may be an adaptor molecule for tau inclusions before their degradation by autophagy. Although the majority of tau filaments in P301S tau transgenic are not ubiquitinated ([@aws143-B1]), p62/SQSTM1 may nonetheless be involved, as it has been shown to play a role in the autophagic degradation of non-ubiquitinated protein aggregates ([@aws143-B52]). The levels of p62/SQSTM1 were similar between P301S tau transgenic mice and wild-type controls, indicating that p62/SQSTM1 synthesis and basal autophagy were not affected in the transgenic mice. In conclusion, we show that activation of autophagy in mice transgenic for human mutant P301S tau decreased the number of tau inclusions and increased nerve cell survival in cerebral cortex and brainstem.
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